	US 12,134,772 B2
	Increasing gene expression
Ci-Di Chen, Boston, MA (US); Ella Zeldich, Boston, MA (US); and Carmela Abraham, Boston, MA (US)
Assigned to Advantage Therapeutics, Inc., Miami, FL (US)
Appl. No. 17/276,320
Filed by Klogenix LLC, Boston, MA (US)
PCT Filed Sep. 6, 2019, PCT No. PCT/US2019/049918 § 371(c)(1), (2) Date Mar. 15, 2021, PCT Pub. No. WO2020/106351, PCT Pub. Date May 28, 2020.
Claims priority of provisional application 62/860,407, filed on Jun. 12, 2019.
Claims priority of provisional application 62/827,471, filed on Apr. 1, 2019.
Claims priority of provisional application 62/770,336, filed on Nov. 21, 2018.
Prior Publication US 2023/0101807 A1, Mar. 30, 2023
Int. Cl. C12N 15/67 (2006.01); A61K 31/713 (2006.01); C12N 9/24 (2006.01); C12N 15/113 (2010.01)

CPC C12N 15/67 (2013.01) [A61K 31/713 (2013.01); C12N 9/2402 (2013.01); C12N 15/113 (2013.01); C12N 2310/113 (2013.01); C12N 2310/14 (2013.01)]

18 Claims

1. A method of increasing expression of a Klotho gene in a cell, the method comprising administering to the cell a nucleic acid that hybridizes to an RNA transcript transcribed from a chromosomal region within or near the Klotho gene, wherein the RNA transcript does not encode a Klotho protein, and wherein the nucleic acid is between about 15 and 50 nucleotides in length and comprises a region of at least 15 nucleotides that is substantially complementary to the RNA transcript.